Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PDE5A | O76074 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | GUCY1A1 | Q02108 | 3/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 3/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929205 | 1.00 | ATM (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL6068600 | 0.91 | CFD (0.49) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL174160 | 0.89 | ATM (0.54) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL2878097 | 0.88 | ADORA3 (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL255820 | 0.88 | ADORA3 (0.50) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL175370 | 0.88 | ATM (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| Hydrochloric Acid SCHEMBL174837 | 0.87 | ADORA3 (0.49) | ATMADORA3KCNH2PDE5AMAPT | |
| Hydrochloric Acid SCHEMBL30507586 | 0.87 | ADORA3 (0.49) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL2883924 | 0.86 | ADORA3 (0.46) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL8220418 | 0.86 | ADORA3 (0.46) | ATMADORA3KCNH2PDE5AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017025981-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-02-16 | — | — | WO | claimed |
| EP-1506193-B9 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-1506193-B3 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2002042300-A1 | NOVEL CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| WO-2001083490-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | disclosed |
| EP-1104421-A1 | 3-(4-AMINO-5-ETHYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO 3,4-B]PYRIDINE | BAYER AG (DE) | 2001-06-06 | — | — | EP | disclosed |
| EP-1102768-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | Bayer Aktiengesellschaft (DE) | 2001-05-30 | — | — | EP | disclosed |
| EP-1102767-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001017998-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000066582-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000006568-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006569-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006567-A1 | 3-(4-AMINO-5-ETHYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | ATM 338/4885ADORA3 1006/4885KCNH2 3135/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | ATM 332/4885ADORA3 1072/4885KCNH2 3222/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | ATM 332/4885ADORA3 1072/4885KCNH2 3222/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | ATM 338/4885ADORA3 1006/4885KCNH2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.